New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent Wired By: Fernanda González 24 October 2026 at 12:30 The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
Login
